Unbiased Analysis of Today's Healthcare Issues
What types of data capacity does the National Academies believe are needed to improve patient-centered outcomes research (PCOR), particularly with respect to health disparities. A report out this month (highlights) highlights some of the data capacity needs and also describes how U.S. Department of Health and Human Services (HHS)’s Office of the Assistant Secretary for…
Last month, the Office of Health Economics published a report titled “Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?” I summarize some of the key challenges and solutions below. Challenge #1: Initial assessment of clinical effectiveness. Since gene therapies often target rare disease, the sample size from clinical trials is often…
Financial Incentives, Not Behavioral Nudges. Ascertainment of Alzheimer’s Disease in claims data. Marketplace insurers denied 18% of in-network claims. What preventive care is free? Changes in life expectancy and health disparities after COVID-19.
How do you measure changes in quality of life for patients with cancer? Today we will review 3 different approaches: health state based, health state with age decrements, and health state with time-to-death (TTD) decrements. Health state based. One common approach is just to use the quality of life of a given health state. For…
What role should digital therapeutics (DTx) play in our treatment landscape? What regulatory and access processes need to be established to be sure these treatments are safe, effective and high value? What evidence is needed to support claims of safety, efficacy and value? These questions and more were tackled as part of an AMCP Partnership…
FDA wants drugs to be more targeted to factors that impact patient’s lives in ways that they care about. To achieve this goal, last month FDA released a third guidance document on patient focused drug development generally applicable to a variety of clinical outcome assessments (COAs), including patient-reported outcome (PRO), observer-reported outcome (ObsRO), clinician-reported outcome…
Some COVID-19 news updates. 66.5% of the world population has received at least one dose of a COVID-19 vaccine. 12.09 billion doses have been administered globally, 5.74 million COVID-19 vaccines are administered each day. Only 17.6% of people in low-income countries have received at least one dose. There have been approximately 550 million cases of COVID-19…
Using data from 2006-2018 across 26 high-income countries, Lichtenberg et al. (2022) measures the relationship between pharmaceutical innovation and longevity. Innovation is measured by “mean vintage…of the drugs used to treat each disease in each country” where vintage is defined as the year of worldwide launch. For the U.S., the authors found that: …the diseases…